110. [IF=3.4] Zhibo Hu et al."Astragaloside IV attenuates podocyte apoptosis via regulating TXNIP/NLRP3/GSDMD signaling pathway in diabetic nephropathy."Diabetology & Metabolic Syndrome.2024 Dec;16:296 109. [IF=6.7] Si-wei Wang et al."Astragaloside IV inhibits retinal pigment epithelial cell senescence and reduces IL-1β mRNA stability by targeting FTO-mediated m6A methylation."PHYTOMEDICINE.2025 Jan;:156408 108. [IF=3.1] Wenjing Liu et al."Characterization of metabolites of ganoderic acids extract from Ganoderma lucidum in rats using UHPLC–MS/MS."JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS.2025 Jun;258:116764 107. [IF=8.7] Liangyin Wei et al."Oxymatrine and astragaloside IV co-loaded liposomes: Scale-up purposes and their enhancement of anti-PD-1 efficacy against breast cancer."Materials Today Bio.2025 Mar;:101634 106. [IF=4.9] Rong Gao et al."Th1/Th2 Immune Imbalance in the Spleen of Mice Induced by Hypobaric Hypoxia Stimulation and Therapeutic Intervention of Astragaloside IV."INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.2025 Jan;26(6):2584 105. [IF=4.4] Wenshuang Wang et al."Kunxinning granules alleviate perimenopausal syndrome by supplementing estrogen deficiency."Frontiers in Pharmacology.2025 Mar;16: 104. [IF=1.5] Qian Xiaojing et al."Qualitative, Quantitative Analysis and Pharmacokinetic Study of Potentially Active Components of Huangxueyishen Decoction Based on UPLC-MS/MS."JOURNAL OF CHROMATOGRAPHIC SCIENCE.2025 Apr;63(4): 103. [IF=3.8] Zicong Wu et al."Astragaloside IV Treats Parkinson’s Disease by Regulating the Proliferation and Differentiation of NSCs through the SHH–Nurr1 Pathway."Stem Cells International.2024 Sep;2024(1):2792909 102. [IF=2.8] Zhu Yuanying et al."New insight into the molecular mechanism of TCM Bufei Huoxue formula for chronic obstructive pulmonary disease based on network pharmacology and experimental verification."JOURNAL OF PHARMACY AND PHARMACOLOGY.2024 Aug;: 101. [IF=3.8] Li Wei et al."Quantitative comparison of bile acid glucuronides sub-metabolome between intrahepatic cholestasis and healthy pregnant women."ANALYTICAL AND BIOANALYTICAL CHEMISTRY.2024 Jul;:1-13 100. [IF=5.6] Zuyu Lu et al."Physicochemical heterogeneity and mechanical separation of the phloem and xylem in Astragalus membranaceus."INDUSTRIAL CROPS AND PRODUCTS.2024 Dec;221:119182 99. [IF=1.3] Hong-Ping Wang et al."Screening of potential α-glucosidase inhibitors from astragalus membranaceus by affinity ultrafiltration screening coupled with UPLC-ESI-Orbitrap-MS method."JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH. 98. [IF=6] Jiaheng Shan et al."β-Cyclocitral from Lavandula?angustifolia Mill. Exerts Anti-Aging Effects on Yeasts and Mammalian Cells via Telomere Protection, Antioxidative Stress, and Autophagy Activation."Antioxidants.2024 Jun;13(6):715 97. [IF=6.7] Yinhuang Gao et al."Buqi Huoxue Tongnao prescription protects against chronic cerebral hypoperfusion via regulating PI3K/AKT and LXRα/CYP7A1 signaling pathways."PHYTOMEDICINE.2024 Sep;132:155844 96. [IF=10.2] Guo Hong et al."Homologous-magnetic dual-targeted metal-organic framework to improve the Anti-hepatocellular carcinoma efficacy of PD-1 inhibitor."JOURNAL OF NANOBIOTECHNOLOGY".2024 Dec;22(1):1-20 95. [IF=2.6] Fan Yang et al."Preliminary Exploration of Potential Active Ingredients and Molecular Mechanisms of Yanggan Yishui Granules for Treating Hypertensive Nephropathy Using UPLC-Q-TOF/MS Coupled with Network Pharmacology and Molecular Docking Strategy."Journal 94. [IF=5.5] Xiangyu Chen et al."Astragaloside IV combined with ligustrazine ameliorates abnormal mitochondrial dynamics via Drp1 SUMO/deSUMOylation in cerebral ischemia–reperfusion injury."CNS Neuroscience & Therapeutics".2024 Apr; 30(4): e14725 93. [IF=7.9] Yun Shan et al."The Role of Macrophage-Derived Exosomes in Reversing Peritoneal Fibrosis: Insights from Astragaloside IV."PHYTOMEDICINE".2024 Apr;:155683 92. [IF=10.8] Xiangtian Deng et al."Microenvironment-responsive smart hydrogels with antibacterial activity and immune regulation for accelerating chronic wound healing."JOURNAL OF CONTROLLED RELEASE".2024 Apr;368:518 91. [IF=5.4] Jialing Sun et al."Investigating the molecular mechanism of Qizhu anticancer prescription in inhibiting hepatocellular carcinoma based on high-resolution mass spectrometry and network pharmacology."JOURNAL OF ETHNOPHARMACOLOGY".2024 Feb;:117985 90. [IF=3.1] Yang Tao et al."Astragaloside IV modulates gut macrophages M1/M2 polarization by reshaping gut microbiota and SCFA in sepsis."SHOCK.2023 Nov;:10.1097/SHK.0000000000002262 89. [IF=5.2] Yang Ma et al."Astragaloside IV Attenuates Programmed Death-Ligand 1-Mediated Immunosuppression during Liver Cancer Development via the miR-135b-5p/CNDP1 Axis."Cancers.2023 Jan;15(20):5048 88. [IF=5.4] Keyan Jiao et al."Glycosides of Buyang Huanwu decoction inhibits inflammation associated with cerebral ischemia-reperfusion via the PINK1/Parkin mitophagy pathway."JOURNAL OF ETHNOPHARMACOLOGY.2024 Jan;:117766 87. [IF=5.4] Wenjuan Ma et al."Uncovering the key pharmacodynamic material basis and possible molecular mechanism of Xiaoke formulation improve insulin resistant through a comprehensive investigation."JOURNAL OF ETHNOPHARMACOLOGY.2024 Apr;323:117752 86. [IF=3.5] Yanyun Guan et al."Astragaloside IV inhibits epithelial-mesenchymal transition and pulmonary fibrosis via lncRNA-ATB/miR-200c/ZEB1 signaling pathway."GENE.2024 Mar;897:148040 85. [IF=17.1] Hong Guo et al."Magnetic Metal–Organic Framework-Based Nanoplatform with Platelet Membrane Coating as a Synergistic Programmed Cell Death Protein 1 Inhibitor against Hepatocellular Carcinoma."ACS Nano.2023;XXXX(XXX):XXX-XXX 84. [IF=3.1] Xi Jie et al."Astragaloside IV restrains pyroptosis and fibrotic development of pulmonary artery smooth muscle cells to ameliorate pulmonary artery hypertension through the PHD2/HIF1α signaling pathway."BMC Pulmonary Medicine.2023 Dec;23(1):1-12 83. [IF=3.1] Yuan Zhang et al."Isolating, Identifying, and Analyzing the Biological Characteristics of Pathogens Causing Postharvest Disease in Fresh Radix?Astragali."Horticulturae.10.3390/horticulturae9091019 82. [IF=5.8] Xingru Peng et al."Novel mPEG-CS-modified flexible liposomes-reinforced thermosensitive sol-gel reversible hydrogels for ocular delivery of multiple drugs with enhanced synergism."COLLOIDS AND SURFACES B-BIOINTERFACES.10.1016/j.colsurfb.2023.113560 81. [IF=1.6] Lu Zhang et al."Astragaloside IV relieves IL-1β-induced human nucleus pulposus cells degeneration through modulating PI3K/Akt signaling pathway."MEDICINE.2023 Aug 18; 102(33): e34815 80. [IF=5.4] Huibo Dai et al."Network pharmacology, molecular docking and experimental verification of the mechanism of huangqi-jixuecao herb pair in treatment of peritoneal fibrosis."JOURNAL OF ETHNOPHARMACOLOGY.2023 Jul;:116874 79. [IF=3.1] Yanmin Wang et al."Study on the dynamic metabolic characteristic of main active ingredients in Danggui Buxue Decoction by liquid chromatography-tandem mass spectrometry based on in situ sequential metabolism strategy."JOURNAL OF SEPARATION SCIENCE.2023 Ju 78. [IF=4.6] Wei Li et al."Characterization of Metabolic Correlations of Ursodeoxycholic Acid with Other Bile Acid Species through In Vitro Sequential Metabolism and Isomer-Focused Identification."MOLECULES.2023 Jan;28(12):4801 77. [IF=5.195] Jiaxiong Yao et al."Systems pharmacology reveals the mechanism of Astragaloside IV in improving immune activity on cyclophosphamide-induced immunosuppressed mice."JOURNAL OF ETHNOPHARMACOLOGY.2023 Sep;313:116533 76. [IF=6.656] Chuanjing Cheng et al."Astragaloside IV targets PRDX6, inhibits the activation of RAC subunit in NADPH oxidase 2 for oxidative damage."PHYTOMEDICINE.2023 Mar;:154795 75. [IF=3.195] Yan, Fanchen et al."Glycoside combinations of Buyang Huanwu decoction ameliorate atherosclerosis via STAT3, HIF-1, and VEGF."NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY.2023 Jan;:1-17 74. [IF=5.195] Zhen Xue et al."Untargeted metabolomics reveals the combination effects and mechanisms of Huangqi-fuzi herb-pair against doxorubicin-induced cardiotoxicity."JOURNAL OF ETHNOPHARMACOLOGY.2023 Apr;305:116109 73. [IF=6.449] Yanmei Li et al."Regional variations and plant compartments shape the community structures of the endophytic microbiome and secondary metabolites of Astragalus mongholicus."INDUSTRIAL CROPS AND PRODUCTS.2023 Feb;192:116037 72. [IF=1.698] Jinyan Wu et al."Chemical Identification and Antioxidant Screening of Bufei Yishen Formula using an Offline DPPH Ultrahigh-Performance Liquid Chromatography Q-Extractive Orbitrap MS/MS."International Journal of Analytical Chemistry.2022 Oct 15;2022:142380 71. [IF=5.168] Pan Wang et al."Discovery and characterization of novel ATP citrate lyase inhibitors from natural products by a luminescence-based assay."CHEMICO-BIOLOGICAL INTERACTIONS.2022 Nov;367:110199 70. [IF=3.887] Xiang-Lin KONG et al."Effect of astragaloside IV and salvianolic acid B on antioxidant stress and vascular endothelial protection in the treatment of atherosclerosis based on metabonomics."Chinese Journal of Natural Medicines.2022 Aug;20:601 69. [IF=6.656] Xinying Fu et al."Glycosides from Buyang Huanwu Decoction inhibit atherosclerotic inflammation via JAK/STAT signaling pathway."PHYTOMEDICINE.2022 Oct;105:154385 68. [IF=4.769] Xinyi Chai et al."Screening of immune cell activators from Astragali Radix using a comprehensive two-dimensional NK-92MI cell membrane chromatography/C18 column/time-of-flight mass spectrometry system."Journal of Pharmaceutical Analysis. 2022 May;: 67. [IF=4.451] Liang Wang et al."Astragaloside IV protects diabetic cardiomyopathy against inflammation and apoptosis via regulating TLR4/MyD88/NF-κB signaling pathway."J Funct Foods. 2022 Jan;88:104905 66. [IF=3.168] Yuqiong Lin et al."Astragaloside IV Ameliorates Streptozotocin Induced Pancreatic β-Cell Apoptosis and Dysfunction Through SIRT1/P53 and Akt/GSK3β/Nrf2 Signaling Pathways."Diabet Metab Synd Ob. 2022 Jan;15:131-140 65. [IF=4.432] Hua Tian et al."Astragaloside IV protects against C/EBP homologous protein-mediated apoptosis in oxidized low-density lipoprotein-treated macrophages by promoting autophagy."Eur J Pharmacol. 2022 Mar;:174912 64. [IF=1.662] Hui Shi et al."Astragaloside IV prevents acute myocardial infarction by inhibiting the TLR4/MyD88/NF-κB signaling pathway."J Food Biochem. 2021 Jul;45(7):e13757 63. [IF=3] Qu Lala et al."Phenotypic assessment and ligand screening of ETA/ETB receptors with label-free dynamic mass redistribution assay."N-S Arch Pharmacol. 2020 Jun;393(6):937-950 62. [IF=3.098] Haifeng Jin et al."Astragaloside IV blocks monocrotaline?induced?pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling."Int J Mol Med. 2021 Feb;47(2):595-606 61. [IF=3.434] Du Xiaoxun et al."Tanshinone IIA and Astragaloside IV Inhibit miR-223/JAK2/STAT1 Signalling Pathway to Alleviate Lipopolysaccharide-Induced Damage in Nucleus Pulposus Cells."Dis Markers. 2021;2021:6554480 60. [IF=3.69] Jingyi Hu et al."Qingchang Huashi Formula attenuates DSS-induced colitis in mice by restoring gut microbiota-metabolism homeostasis and goblet cell function."J Ethnopharmacol. 2021 Feb;266:113394 59. [IF=3.69] Xiaoping Wang et al."Baoyuan decoction ameliorates apoptosis via AT1-CARP signaling pathway in H9C2 cells and heart failure post-acute myocardial infarction rats."J Ethnopharmacol. 2020 Apr;252:112536 58. [IF=3.7] Jing-Jing Yang et al."Astragaloside IV enhances GATA-4 mediated myocardial protection effect in hypoxia/reoxygenation injured H9c2 cells."Nutr Metab Cardiovas. 2020 May;30:829 57. [IF=3.882] Kunpeng Yin et al."Lanthanide Metal–Organic Framework-Based Fluorescent Sensor Arrays to Discriminate and Quantify Ingredients of Natural Medicine."Langmuir. 2021;37(17):5321–5328 56. [IF=3.935] Yu-li Jiang et al."HPLC fingerprinting-based multivariate analysis of chemical components in Tetrastigma Hemsleyanum Diels et Gilg: Correlation to their antioxidant and neuraminidase inhibition activities."J Pharmaceut Biomed. 2021 Oct;205:114314 55. [IF=4.225] Zhang Wei et al."Five Active Components Compatibility of Astragali Radix and Angelicae Sinensis Radix Protect Hematopoietic Function Against Cyclophosphamide-Induced Injury in Mice and t-BHP–Induced Injury in HSCs."Front Pharmacol. 2019 Aug;0:936 54. [IF=4.36] Pin Gong et al."Hypoglycemic effect of astragaloside IV via modulating gut microbiota and regulating AMPK/SIRT1 and PI3K/AKT pathway."J Ethnopharmacol. 2021 Dec;281:114558 53. [IF=6.081] Tongji Liu et al."Improvement Effect of Lotus Leaf Flavonoids on Carbon Tetrachloride-Induced Liver Injury in Mice."Biomedicines. 2020 Feb;8(2):41 52. [IF=1.146] Han Gao et al."Proliferation and committed differentiation into dopamine neurons of neural stem cells induced by the active ingredients of radix astragali."Neuroreport. 2018 May 2; 29(7): 577–582 51. [IF=3.098] Xiao Chen et al."Astragaloside IV ameliorates high glucose?induced renal tubular epithelial?mesenchymal transition by blocking mTORC1/p70S6K signaling in HK?2 cells."Int J Mol Med. 2019 Feb;43(2):709-716 50. [IF=4.213] Qiangyuan Fan et al."Improved oral bioavailability of notoginsenoside R1 with sodium glycocholate-mediated liposomes: Preparation by supercritical fluid technology and evaluation in vitro and in vivo."Int J Pharmaceut. 2018 Dec;552:360 49. [IF=4.354] Ting Liu et al."Synthetic Access Toward Cycloastragenol Glycosides."J Org Chem. 2017;82(8):4170–4178 48. [IF=4.759] Yuping Zhang et al."On-line surface plasmon resonance-high performance liquid chromatography–tandem mass spectrometry for analysis of human serum albumin binders from Radix Astragali."J Chromatogr A. 2013 Jun;1293:92 47. [IF=7.514] Yuping Zhang et al."Integration of magnetic solid phase fishing and off-line two-dimensional high-performance liquid chromatography–diode array detector–mass spectrometry for screening and identification of human serum albumin binders from Radix Astragali 46. Yang, Jing-Jing, et al. "Astragaloside IV enhances GATA-4 mediated myocardial protection effect in hypoxia/reoxygenation injured H9c2 cells." Nutrition, Metabolism and Cardiovascular Diseases 30.5 (2020): 829-842.https://doi.org/10.1016/j.numecd.2020.01.00 45. Fan, Qiangyuan, et al. "Improved oral bioavailability of notoginsenoside R1 with sodium glycocholate-mediated liposomes: preparation by supercritical fluid technology and evaluation in vitro and in vivo."?International journal of pharmaceutics?552.1-2 (201 44. Ting Liu, Jin-Xi Liao, Yang Hu, Yuan-Hong Tu, and Jian-Song Sun The Journal of Organic Chemistry 2017 82 (8), 4170-4178 DOI: 10.1021/acs.joc.7b00080 43. Liu, Tongji, et al. "Improvement effect of lotus leaf flavonoids on carbon tetrachloride-induced liver injury in mice." Biomedicines 8.2 (2020): 41.https://doi.org/10.3390/biomedicines8020041 42. Wang, Xiaoping, et al. "Baoyuan decoction ameliorates apoptosis via AT1-CARP signaling pathway in H9C2 cells and heart failure post-acute myocardial infarction rats." Journal of ethnopharmacology 252 (2020): 112536.https://doi.org/10.1016/j.jep.2019.112536 41. 范小龍,陳冉,吳婉琴,劉國姣,黃坤,江豐.液相色譜串聯質譜法測定食品中淫羊藿苷等20種功能成分[J].食品與機械,2021,37(01):86-93+98. 40. 田文倉. 不同生長年限及采收期子洲黃芪鑒別特征及其質量、產量差異分析[D].北京中醫(yī)藥大學,2020. 39. 徐芳芳,張秀莉,侯滔,曲臘臘,王紀霞,劉艷芳,梁鑫淼.天然產物中FFA1受體新激動劑的發(fā)現與研究[J].上海中醫(yī)藥大學學報,2021,35(01):12-19. [4]宮夢琪,孫倩,李振.天麻中天麻素提取工藝優(yōu)化及抑制α-葡萄糖苷酶活性研究[J].中國果菜,2020,40(09):14-17+23. 38. 彭勝男,陶琰心,洪婷,楊海燕,黃青.黃芪甲苷通過mTORC1通路調控IgA腎病大鼠脾淋巴細胞分化[J].中國免疫學雜志,2021,37(04):421-425. 37. 張悅,于學煒,于宏川,仲偉一,楊陽.黃芪甲苷調節(jié)miR-21基因抑制腎癌細胞增殖和誘導細胞凋亡的機制探討[J].現代腫瘤醫(yī)學,2020,28(18):3145-3150. 36. 曾廣偉,安慧仙,方東,高釗,賈建軍,朱舜明.黃芪甲苷抑制缺血再灌注誘導的大鼠心肌細胞凋亡[J].現代生物醫(yī)學進展,2020,20(24):4612-4617. 35. 彭勝男,陶琰心,洪婷,楊海燕,黃青.黃芪甲苷通過mTORC1通路調控IgA腎病大鼠脾淋巴細胞分化[J].中國免疫學雜志,2021,37(04):421-425. 34. 馮美杰,李蕾,王穎航,徐兢鴻,潘志.黃芪甲苷對人類風濕關節(jié)炎成纖維樣滑膜細胞增殖及白細胞介素6分泌的影響[J].中國中醫(yī)基礎醫(yī)學雜志,2020,26(10):1484-1487. 33. 程歡,米雅慧,劉明平,于洋,黎同明.黃芪多糖、黃芪甲苷對大黃酸腸吸收的影響[J].中藥新藥與臨床藥理,2021,32(02):240-244. 32. 姚萱航,劉翠晶,常晶茹,張雪薇,劉霞.2種類型膜莢黃芪主要藥效成分含量及關鍵酶基因表達量差異研究[J].中草藥,2021,52(07):2072-2081. 31. 馮紫薇. 子洲黃芪飲片質量等級標準研究[D].北京中醫(yī)藥大學,2020. 30. 趙宏月,張東偉,龐琳琳,張歡,于睿.黃芪甲苷及人參皂苷Rg1對高脂大鼠心肌缺血再灌注損傷后心肌細胞凋亡的影響[J].遼寧中醫(yī)雜志,2021,48(02):188-191. 29. 孫樂,吳鵬,王春艷,張學蘭,金玉翠,劉海濱.黃芪飲片炮制工藝優(yōu)選[J].時珍國醫(yī)國藥,2020,31(07):1616-1619. 28. 張素清,陳冰,陳思邈,董靜怡,陳偉燕,張宇燕.R語言與正交試驗分析處理優(yōu)化黃芪中黃芪甲苷提取工藝的比較[J].中國中醫(yī)急癥,2020,29(08):1420-1423. 27. 支旭然 劉洪濤 吳茵 等. UPLC-MS/MS法同時測定腎康注射液中7個有效成分[J]. 藥物分析雜志 2017 037(001):37-42. 26. 燕玉奎, 郭玫, 邵晶,等. 紅芪及其不同提取部位中主要活性成分的含量測定[J]. 中獸醫(yī)醫(yī)藥雜志, 2020, v.39;No.220(01):22-25. 25. 張婕,梁程程,楊愛仲,齊聰.增免抑瘤方及有效組分對卵巢癌干細胞裸鼠移植瘤Notch/Jagged1信號通路的影響[J].中國實驗方劑學雜志,2020,26(15):46-53. 24. 鄒龍, 李歡歡, 劉輝,等. 補陽還五湯總苷膠囊的制備工藝優(yōu)選. 中國實驗方劑學雜志. 23. 鄒龍 劉輝 李仲秋 等. HPLC測定補陽還五湯總苷中黃芪甲苷和芍藥苷的含量[J]. 湖南中醫(yī)藥大學學報 2012 32(005):39-42. 22. 李富欣, 于蓓蓓, 劉瑾,等. 茯黃顆粒的質量標準研究[J]. 西部中醫(yī)藥, 2019, 032(002):P.44-48. 21. 何昊 許暢 王興中 蘇力 張家旭. 四種不同方法提取黃芪中黃芪甲苷的對比研究[J]. 化工科技(3期):25-28. 20. 韋赫, 程林, 吳培,等. 黃芪皂苷生物合成對短期水分變化的響應[J]. 中國中藥雜志, 2019, 44(03):39-45. 19. 李楊, 郭超, 張小平,等. 黃芪皂苷-氫氧化鋁佐劑復合物對bFGF腫瘤疫苗抗乳腺癌活性的影響[J]. 河西學院學報, 2018, 34(05):32-37. 18. 成鵬,白銀亮,胡彩莉,連佛彥,周海宇.黃芪甲苷通過調控FoxO3a/Wnt2/β-catenin通路抑制去卵巢大鼠骨質疏松的作用[J].中國實驗方劑學雜志,2018,24(15):161-166. 17. 張悅,于學煒,于宏川,仲偉一,楊陽.黃芪甲苷調節(jié)miR-21基因抑制腎癌細胞增殖和誘導細胞凋亡的機制探討[J].現代腫瘤醫(yī)學,2020,28(18):3145-3150. 16. 張怡, 靳曉飛, 周曉紅,等. 黃芪甲苷調控自噬抑制缺氧缺糖/復氧復糖HT22細胞凋亡[J]. 中國藥理學通報, 2019, 035(004):519-524. 15. 俞曼殊, 史俊, 趙君誼,等. 黃芪甲苷調控Akt信號通路阻抑人腹膜間皮細胞間充質轉化的實驗研究[J]. 南京中醫(yī)藥大學學報, 2019, 35(01):53-57. 14. 劉晨旭,張玫,楊洋,魏鵬翔,魏群利.黃芪甲苷對高糖誘導下大鼠腎小球系膜細胞TGF-β1/Smad信號通路的影響[J].徐州醫(yī)科大學學報,2019,39(09):641-643. 13. 賈力維, 沃曉嫚, 王謙博,等. 黃芪甲苷對非小細胞肺癌A549細胞增殖及凋亡相關蛋白表達的影響[J]. 黑龍江大學自然科學學報, 2019, 036(001):84-89. 12. 熊莉,呂夢娟,竇德宇,馬玉紅.黃芪甲苷對血管緊張素Ⅱ誘導腎小球系膜細胞增殖及炎癥因子表達的影響[J].中國應用生理學雜志,2018,34(05):414-417+421. 11. 趙彩萍,劉翠玲,梁爽,李欣蓉,柳雪蕾,朱美玲.黃芪甲苷對脂多糖誘導人胃黏膜上皮細胞GES-1的抗炎作用及機制研究[J].中藥新藥與臨床藥理,2020,31(08):918-923. 10. 張吉, 臧東鈺. 黃芪甲苷對急性肺損傷大鼠內質網應激介導影響[J]. 中國民族民間醫(yī)藥, 2014, 000(015):19-20. 9. 武建毅, 沈清, 金赟潔,等. 黃芪甲苷對BALB/C小鼠肝癌H22腹水瘤抑制作用及機制[J]. 中國藥物警戒, 2016, 13(003):138-142. 8. 朱易平, 李茹柳, 時玉霞,等. 黃芪總皂苷對IEC-6細胞增殖及相關蛋白表達的影響[J]. 中藥新藥與臨床藥理, 2019, 30(01):60-65. 7. 倪琳, 魏學冰, 陳德道,等. 黃芪烏梅降糖顆粒的制備工藝與質量分析[J]. 海峽藥學, 2020, v.32;No.240(01):10-15. 6. 李玉美, 陳新梅, 徐溢明,等. 納秒脈沖電場滅菌對舒心糖漿質量影響的初步研究[J]. 化工時刊, 2015(04):31-32+52. 5. 孟琦, 寶麗, 張燁,等. 基于腸道菌群調節(jié)的小檗堿和黃芪甲苷聯用降糖機制研究[J]. 食品與藥品, 2020(3):169-175. 4. 孫銘憶, 李冰韶, 王永潔,等. 基于模糊層次分析法優(yōu)選復方黃芪水浸膏提取工藝路線[J]. 中草藥, 2018. 3. 陳開, 周靜, 李敏,等. 基于大孔樹脂的黃芪中黃芪甲苷提取液純化工藝研究[J]. 中國中醫(yī)急癥, 2017, 26(011):1881-1883. 2. 袁一凡 陳曉月 劉保霞 劉笑 李瑞宏 祁金龍 賈慶忠.UPLC-MS/MS法同時測定康艾注射液中11種成分[J].中草藥 2017 48(13):2660-2665. 1. 張素清 陳冰 陳思邈 等. R語言與正交試驗分析處理優(yōu)化黃芪中黃芪甲苷提取工藝的比較[J]. 中國中醫(yī)急癥 2020(8).